204 related articles for article (PubMed ID: 35615981)
21. LNCAROD enhances hepatocellular carcinoma malignancy by activating glycolysis through induction of pyruvate kinase isoform PKM2.
Jia G; Wang Y; Lin C; Lai S; Dai H; Wang Z; Dai L; Su H; Song Y; Zhang N; Feng Y; Tang B
J Exp Clin Cancer Res; 2021 Sep; 40(1):299. PubMed ID: 34551796
[TBL] [Abstract][Full Text] [Related]
22. Prohibitin 1 Regulates the H19-Igf2 Axis and Proliferation in Hepatocytes.
Ramani K; Mavila N; Ko KS; Mato JM; Lu SC
J Biol Chem; 2016 Nov; 291(46):24148-24159. PubMed ID: 27687727
[TBL] [Abstract][Full Text] [Related]
23. Splicing factor SRSF3 represses translation of p21
Kim J; Park RY; Kee Y; Jeong S; Ohn T
Cell Death Dis; 2022 Nov; 13(11):933. PubMed ID: 36344491
[TBL] [Abstract][Full Text] [Related]
24. Transforming growth factor-β signaling in hepatocytes promotes hepatic fibrosis and carcinogenesis in mice with hepatocyte-specific deletion of TAK1.
Yang L; Inokuchi S; Roh YS; Song J; Loomba R; Park EJ; Seki E
Gastroenterology; 2013 May; 144(5):1042-1054.e4. PubMed ID: 23391818
[TBL] [Abstract][Full Text] [Related]
25. Loss of Splicing Factor SRSF3 Impairs Lipophagy Through Ubiquitination and Degradation of Syntaxin17 in Hepatocytes.
Li Y; Wang T; Liao Q; Luo X; Wang X; Zeng S; You M; Chen Y; Ruan XZ
J Lipid Res; 2023 Mar; 64(3):100342. PubMed ID: 36764525
[TBL] [Abstract][Full Text] [Related]
26. Inclusion of hnRNP L Alternative Exon 7 Is Associated with Good Prognosis and Inhibited by Oncogene SRSF3 in Head and Neck Squamous Cell Carcinoma.
Xu L; Shen J; Jia J; Jia R
Biomed Res Int; 2019; 2019():9612425. PubMed ID: 31828152
[TBL] [Abstract][Full Text] [Related]
27. Over-expression of long non-coding RNA insulin-like growth factor 2-antisense suppressed hepatocellular carcinoma cell proliferation and metastasis by regulating the microRNA-520h/cyclin-dependent kinase inhibitor 1A signaling pathway.
Huang Z; Su G; Bi X; Zhang L; Xu Z; Wang G
Bioengineered; 2021 Dec; 12(1):6952-6966. PubMed ID: 34516353
[TBL] [Abstract][Full Text] [Related]
28. IGF2 mRNA binding protein p62/IMP2-2 in hepatocellular carcinoma: antiapoptotic action is independent of IGF2/PI3K signaling.
Kessler SM; Pokorny J; Zimmer V; Laggai S; Lammert F; Bohle RM; Kiemer AK
Am J Physiol Gastrointest Liver Physiol; 2013 Feb; 304(4):G328-36. PubMed ID: 23257922
[TBL] [Abstract][Full Text] [Related]
29. Loss of TDP43 inhibits progression of triple-negative breast cancer in coordination with SRSF3.
Ke H; Zhao L; Zhang H; Feng X; Xu H; Hao J; Wang S; Yang Q; Zou L; Su X; Wang L; Wu C; Wang Y; Nie J; Jiao B
Proc Natl Acad Sci U S A; 2018 Apr; 115(15):E3426-E3435. PubMed ID: 29581274
[TBL] [Abstract][Full Text] [Related]
30. Hepatocyte growth factor enhances alternative splicing of the Kruppel-like factor 6 (KLF6) tumor suppressor to promote growth through SRSF1.
Muñoz Ú; Puche JE; Hannivoort R; Lang UE; Cohen-Naftaly M; Friedman SL
Mol Cancer Res; 2012 Sep; 10(9):1216-27. PubMed ID: 22859706
[TBL] [Abstract][Full Text] [Related]
31. [Study on the expression and genomic imprinting status of insulin-like growth factor 2 gene in hepatocellular carcinoma].
Li H; Zhang N
Zhonghua Gan Zang Bing Za Zhi; 2004 Jun; 12(6):347-9. PubMed ID: 15225429
[TBL] [Abstract][Full Text] [Related]
32. Circular RNA Circ100084 functions as sponge of miR‑23a‑5p to regulate IGF2 expression in hepatocellular carcinoma.
Yang J; Li Y; Yu Z; Zhou Y; Tu J; Lou J; Wang Y
Mol Med Rep; 2020 Jun; 21(6):2395-2404. PubMed ID: 32323783
[TBL] [Abstract][Full Text] [Related]
33. Oncogenic splicing factor SRSF3 regulates ILF3 alternative splicing to promote cancer cell proliferation and transformation.
Jia R; Ajiro M; Yu L; McCoy P; Zheng ZM
RNA; 2019 May; 25(5):630-644. PubMed ID: 30796096
[TBL] [Abstract][Full Text] [Related]
34. TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis.
Wang X; Zeldin S; Shi H; Zhu C; Saito Y; Corey KE; Osganian SA; Remotti HE; Verna EC; Pajvani UB; Schwabe RF; Tabas I
J Hepatol; 2022 Apr; 76(4):910-920. PubMed ID: 34902531
[TBL] [Abstract][Full Text] [Related]
35. Alteration of splicing factors' expression during liver disease progression: impact on hepatocellular carcinoma outcome.
Wang H; Lekbaby B; Fares N; Augustin J; Attout T; Schnuriger A; Cassard AM; Panasyuk G; Perlemuter G; Bieche I; Vacher S; Selves J; Péron JM; Bancel B; Merle P; Kremsdorf D; Hall J; Chemin I; Soussan P
Hepatol Int; 2019 Jul; 13(4):454-467. PubMed ID: 31140152
[TBL] [Abstract][Full Text] [Related]
36. Homeobox B9 Promotes Colon Cancer Progression by Targeting SRSF3.
Yuan L; Cheng F; Wu Z; Li X; Shen W
Dig Dis Sci; 2023 Aug; 68(8):3324-3340. PubMed ID: 37258980
[TBL] [Abstract][Full Text] [Related]
37. Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma.
Dong ZZ; Yao DF; Yao DB; Wu XH; Wu W; Qiu LW; Jiang DR; Zhu JH; Meng XY
World J Gastroenterol; 2005 Aug; 11(30):4655-60. PubMed ID: 16094705
[TBL] [Abstract][Full Text] [Related]
38. RNA binding protein serine/arginine splicing factor 1 promotes the proliferation, migration and invasion of hepatocellular carcinoma by interacting with RecQ protein-like 4 mRNA.
Ye Y; Yu F; Li Z; Xie Y; Yu X
Bioengineered; 2021 Dec; 12(1):6144-6154. PubMed ID: 34486474
[TBL] [Abstract][Full Text] [Related]
39. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.
Frau M; Feo F; Pascale RM
J Hepatol; 2013 Oct; 59(4):830-41. PubMed ID: 23665184
[TBL] [Abstract][Full Text] [Related]
40. SRSF3 promotes pluripotency through
Ratnadiwakara M; Archer SK; Dent CI; Ruiz De Los Mozos I; Beilharz TH; Knaupp AS; Nefzger CM; Polo JM; Anko ML
Elife; 2018 May; 7():. PubMed ID: 29741478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
